Navigation Links
MIT Receives First ARRONAX Shipment, Launching Strontium-82 Validation Project
Date:2/21/2012

LUBBOCK, Texas, Feb. 21, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 16, 2012, MIT, received its first shipment of strontium-82(Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France. 

This historic event marks the first shipment of Sr-82 to be received by a private, non-government, entity in the U.S. in support of Sr-82 production. The receipt of this material also marks the beginning of MIT's validation efforts in order to qualify Sr-82 product material as Active Pharmaceutical Ingredient (API).

Over the next six months MIT will continue to obtain Sr-82 target solutions, from foreign irradiators at the facility in Lubbock, Texas.  MIT will conduct the critical processing procedures for final purification into API grade Sr-82.  Validation of the API grade Sr-82 product material is key to the Positron/MIT 2012 Drug Master File submission to the U.S. FDA.

"With the receipt of Sr-82 from ARRONAX, Positron and MIT have achieved an incredible milestone," states MIT President and Positron Pharmaceutical, Chief Technical Officer, Jason Kitten. "Up until this point in time, the Department of Energy was the only organization in the United States capable of processing Sr-82 material. By executing our plans, MIT is well positioned to meet the Drug Master File qualifications, which will further advance and accelerate Positron's Sr-82 mission. Positron continues its progress and is on schedule to meet 2012 Sr-82 supply objectives. Positron's goal of solidifying and advancing cardiac PET's progression in the U.S. is well underway."

About Positron:

Positron Corporation is a leading molecular imaging healthcare company providing innovative nuclear medicine technologies and solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.

Forward Looking Statements:

Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Positron Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amsterdam Molecular Therapeutics Receives Request for Further Information From CHMP on Glybera®
2. The Apothecary Shops Receives Exclusive Distribution Rights for Mitosol®
3. Waltonen Engineering, Inc., Receives GSA Schedule
4. Cardinal Health Canada Inc. Receives Competition Bureau Clearance for Acquisition of Futuremed
5. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
6. Total Artificial Heart Patient Receives Donor Heart 15 Years After Decision to Donate Wifes Organs
7. Delcath Receives Regulatory Approval to Commercialize Hepatic CHEMOSAT® Delivery System in Australia
8. Large Orthopedic Practice Receives Vizteks Complete Orthopedic DR+PACS Bundle
9. Ocular Therapeutix, Inc. Receives IDE Approval to Conduct a Pivotal Clinical Trial for ReSure™ Sealant
10. United Therapeutics Receives Paragraph IV Notice Letter for Remodulin
11. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... SYDNEY , June 26, 2016 One of ... , has announced the formation of a new biotechnology company, Noxopharm ... raise $6m in an IPO and to list on the ASX. ... drug candidate, NOX66, ready to enter a Phase 1 clinical study ... been designed to address one of the biggest problems facing cancer ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... 27, 2016 , ... "FCPX editors can now reveal their media with growing ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color brings ... users can now reveal the media of their split screens with growing colorful panels. ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... cutting edge technology to revolutionize the emergency ambulance transport experience for the millions ... aware of how Uber has disrupted the taxi industry through the use of ...
Breaking Medicine News(10 mins):